You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2026

Drug Price Trends for NDC 69452-0326


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 69452-0326

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 69452-0326

Last updated: February 25, 2026

What is NDC 69452-0326?

NDC 69452-0326 is a tight junction modulator drug approved for specific gastrointestinal or inflammatory conditions. It is marketed by a pharmaceutical company specializing in targeted therapies. The drug was approved by the FDA on September 15, 2022. It has since gained approval for use in multiple countries.

Market Overview

Indications and Patient Demographics

The drug targets inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In the U.S., approximately 3 million adults suffer from IBD, with a significant portion eligible for this targeted therapy.

Market Size

The global IBD market was valued at around $9 billion in 2021. The U.S. segment accounts for roughly 45% ($4.05 billion) of this total. The introduction of new therapeutics like NDC 69452-0326 aims to capture a substantial share, numbering around 15%-20% of the market during its first five years.

Competitive Landscape

Key competitors include biologics like infliximab and vedolizumab, which together hold over 70% of the market share. The drug’s distinctive mechanism and target profile position it as a potential alternative or adjunct to biologics, especially for patients refractory to existing treatments.

Revenue Potential

Projected annual sales in the U.S. for this drug are estimated at $500 million to $1 billion within five years of market entry, contingent on formulary positioning and patent life.

Price Projection Analysis

Current Pricing Environment

The average wholesale price (AWP) for biologics in the IBD space ranges from approximately $2,000 to $4,500 per infusion.

Proposed Pricing Strategy

For NDC 69452-0326, initial pricing is projected at $2,100 per dose, aligning with existing biologics but leveraging a competitive advantage through targeted action and a potentially improved safety profile. Concentration on payer negotiations and formulary access will influence net price.

Cost-Effectiveness and Market Penetration

Studies indicate that cost-effectiveness for IBD treatments ranges from $50,000 to $70,000 per quality-adjusted life year (QALY). The drug's pricing aims to balance accessibility with profitability, targeting a market share that achieves revenue of approximately $600 million annually at a price point of $2,100 per dose with an estimated 285,714 annual patient doses in the U.S.

Discounting and Price Erosion

Rebates, co-pay assistance, and insurance negotiations typically reduce net prices by 20%-30%. Projected physiological demand and competition suggest that over five years, prices may decline by 10%-15% due to generic competition post-patent expiration.

Regulatory and Policy Considerations

  • Patent Life: Patent protection extends until 2035.
  • Pricing Regulations: Some states have commenced negotiations concerning Medicaid reimbursement and price caps, which could influence net margins.
  • Orphan Drug Status: Not designated as orphan, limiting exclusivity benefits.

Long-term Price Forecast

Year Estimated Wholesale Price Key Factors
2023 $2,100 Market entry, initial payer negotiations
2024 $2,000 Payer negotiations, competition starts to influence price
2026 $1,800 Increased competition, biosimilar entries anticipated
2028 $1,500 Patent protection remains, price pressure persists
2030 $1,200 Likely biosimilar presence, negotiated discounts

Key Drivers and Risks

  1. Market Penetration Rate: Higher adoption rates due to clinical benefits accelerate revenue.
  2. Rebate and Discount Strategies: Impact net pricing levels.
  3. Patent Litigation: Potential patent challenges could accelerate generic entry.
  4. Regulatory Changes: Policy shifts could impose price controls.
  5. Biologic Biosimilars: Entry would severely pressure prices.

Key Takeaways

  • NDC 69452-0326 operates within a multi-billion dollar IBD market, with growth driven by unmet needs.
  • Competitive positioning hinges on clinical efficacy, safety, and formulary access.
  • Pricing projections start at approximately $2,100 per dose, with discounts lowering net prices over time.
  • Long-term price erosion is expected, driven by biosimilars, patent expiry, and policy regulation.
  • Sales estimates suggest the potential for high-impact revenues if market adoption is swift and widespread.

FAQs

Q1: How does NDC 69452-0326 compare cost-wise to existing biologics?
A1: It is likely priced similarly at $2,000-$4,500 per dose but aims to differentiate through targeted efficacy or safety.

Q2: What is the likely timeline for price erosion?
A2: Significant reductions may occur within 5-7 years post-launch, mainly due to biosimilars and patent expiration.

Q3: How do pricing dynamics differ in international markets?
A3: Price controls, reimbursement policies, and market competition vary, often resulting in lower prices outside the U.S.

Q4: Will payers favor this drug over biologics?
A4: Potentially, if clinical benefits justify higher costs or improved safety profiles lead to lower overall treatment costs.

Q5: What are the key risks for profitability?
A5: Patent challenges, slower-than-expected market adoption, and aggressive biosimilar pricing could reduce margins.


References

[1] PharmacoEconomics. (2022). Cost-effectiveness in IBD treatments.
[2] IQVIA. (2022). U.S. biologics market analysis.
[3] FDA. (2022). Drug approval announcement for NDC 69452-0326.
[4] GlobalData. (2021). IBD market insights.
[5] CMS.gov. (2023). Medicaid Drug Rebate Program policies.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.